Related Experiment Video
Updated: Dec 8, 2025
06:24
Minimal Erythema Dose MED Testing
Published on: May 28, 2013
42.6K
A case of dapsone-induced methaemoglobinaemia
Yee Ann Tan1, Kai Choon Ng1, Seng Wee Cheo2
1Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.
Clinical Medicine (London, England)
|September 16, 2020
Summary
Drug-induced methaemoglobinaemia is a serious condition, often caused by medications. This case highlights successful treatment of dapsone-induced methaemoglobinaemia using intravenous methylene blue.
Area of Science:
- Clinical Medicine
- Pharmacology
Background:
- Methaemoglobinaemia is a rare but severe condition.
- It can be congenital or acquired, with drug-induced cases being most common.
- Recognizing symptoms like dyspnoea and desaturation is crucial.
Observation:
- A case of dapsone-induced methaemoglobinaemia is presented.
- The patient exhibited typical clinical signs of methaemoglobinaemia.
Findings:
- Dapsone is identified as a causative agent for methaemoglobinaemia.
- Intravenous methylene blue proved effective in treating the condition.
Implications:
- This case underscores the importance of considering drug-induced methaemoglobinaemia in differential diagnoses.
- Intravenous methylene blue is a viable and successful treatment option.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
274
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
274
01:29Therapeutic Drug Monitoring: Affecting Factors
105
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
105